Although immunotherapy targeting immune checkpoints such as PD‐L1/PD‐1 and CTLA4 has shown promising results in enhancing the immune response against CSCC, the overall response rates remain relatively modest, ranging from 4% to 26%.[26, 27, 28] This limited efficacy may be attributed to the TIME, which plays a critical role in tumor progression and significantly affects treatment outcomes.[29, 30] In addition, extensive studies suggest that metabolism is a key determinant of antitumor immune response within the TIME,[31, 32] yet its role in CSCC remains largely unexplored. The gene discussed is PDCD1; the disease is neoplasm.